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Introduction
Understanding the complex causes of disease and the inabili-
ty of some tissues to repair following injury is a major prior-
ity in biomedical research. Historically, biomedical research 
has followed a “cell-centric” model to explain and treat the 
progression and pathophysiology of disease. Considering 
the role of the extracellular matrix (ECM) in many diseases 
is a relatively recent and departing approach. Though many 
diseases are manifested by cellular insufficiencies, the en-
vironments in which the cells reside likely contribute and 
initiate many pathophysiologic mechanisms. In this review, 
we discuss one example of this interaction in a very unlikely 
place, the central nervous system (CNS). 
Until recently, the study of the CNS was predominated by 
a “neuro-centric” model. The neuron is the “processor” cell 
of the CNS. The neuron receives chemical signals, translates 
them into electrical signals, and passes this message over to 
the next neuron in a re-translated chemical signal. This pro-
cess, known as synaptic signaling, is the work of the neuron. 
However, the other three major cells of the CNS also play 
important roles in proper functioning. Astrocytes, oligoden-
drocytes and microglia regulate the strength, response, rate, 
and structure of neuronal signaling (Doretto et al., 2011; 
Jourdain et al., 2007; Perea et al., 2009; Wake et al., 2009). 
In addition, the astrocyte regulates the amount of chemical 
signal reaching the neuron, the amount of neurotransmitter 
stored for release, energy demands, and ionic homeostasis 
(Belanger et al., 2011; Beller et al., 2011; Haydon and Carmi-
gnoto, 2006; Mack and Wolburg, 2013). Most importantly, 
these three glial types contribute to the production of inte-
gral ECM components, specifically proteoglycans (Jander 
and Stoll, 1996; Jones et al., 2002; Lander et al., 1998; Shioi et 
al., 1995).
Our understanding of the ECM’s function in the CNS is 
miniscule compared to our functional knowledge of the var-
ious CNS cell types themselves. Advances, which have grad-
ually appeared over the past few decades, implicate the ECM 
as a dynamic and important contributor to the development 
of the CNS, as well as to the normal and aberrant function 
of the CNS. A major impetus to investigate the role of the 
ECM in the CNS was the observed interaction of proteogly-
cans with elongating neurons.   
Proteoglycans are a complex component of the 
extracellular matrix
Proteoglycans (PGs) are complex molecules comprised of a 
core protein that is glycosylated and contains various types 
of carbohydrate chains. PGs were originally isolated from 
cartilage tissue in 1891. At this time, PGs’ sole biological 
function was believed to be as a molecule to fill space and 
supply structural support within the extracellular matrix 
(ECM) (for review: Yanagishita, 1993). Contrast this as-
sessment with the current view of the ECM’s role in the 
progression of disease, which has more recently gained great 
attention (Cox and Erler, 2011; Curinga et al., 2008; Lu et 
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al., 2011; Snow, 2011). In all, the ECM plays an important 
role in development, regulation of synapses, the progression 
of neurodegenerative disease, and repair following injury 
(Fawcett and Asher, 1999; Franco and Muller, 2011; Lukes et 
al., 1999; Pyka et al., 2011). Of the many components of the 
ECM, proteoglycans appear to be the major influencer in the 
ECM’s role in CNS physiology (Fitch and Silver, 2008; Gal-
trey and Fawcett, 2007; Hartmann and Maurer, 2001). 
Proteoglycans
There are three major classes of PG including heparan sulfate 
proteoglycans (HSPGs), chondroitin sulfate proteoglycans 
(CSPGs), and keratan sulfate proteoglycans (KSPGs). Each 
class of proteoglycan is classified by the type of carbohydrate 
chain attached to the core protein. Of particular interest to 
CNS physiology are the CSPGs and HSPGs, which play piv-
otal roles in repair and reorganization following CNS injury 
(Carulli et al., 2005; Galtrey and Fawcett, 2007; Jones et al., 
2003).
CSPGs are currently the most widely discussed proteogly-
can in the field of neuronal regeneration. In the late 1980s, 
when initial discoveries were being made about CSPGs and/
or their carbohydrate side chains, and affects on axonal out-
growth (Carbonetto et al., 1983; Verna et al, 1989; Snow et al., 
1990 a and b), conference presentations about CPSGs, e.g., the 
Society for Neuroscience annual meeting, consisted of only a 
few abstracts on the topic, while in 2013, there were > 50 ab-
stracts devoted to CSPGs alone, and a magnitude more devot-
ed to the involvement of ECM components in outgrowth and 
regeneration, as determined by titles alone (SfN Proceedings; 
website; 2013). Clearly, there has been an explosion of interest 
and pronounced scientific advancement made on this topic. 
CSPGs
CSPGs are linked to carbohydrate chains containing 
N-acetylgalactosamine (GalNAc) and glucuronic acid (GlcA)
(Hardingham and Fosang, 1992; Poole, 1986), and exist in 
both cell membrane bound, excreted and ECM embedded 
forms. The family of CSPGs is highly variable having multi-
ple core proteins, differing number and length of associated 
sugar chains, as well as a variety of differing sulfation pat-
terns, which imbue diversity of function. The GlcA can be 
sulfated in the 2-carbon position, referred to as CS-2. The 
GalNAc sugar amine can be sulfated at either the 4- or 6- 
position, or at both the 4- and 6- position (DeLuca et al., 
1973). These are referred to as CS-2, CS-4, CS-6, or CS-4,6 
respectively (Figure 1A, B).  
HSPGs
The HSPG family of PGs contain both cell membrane bound 
and excreted forms. Major transmembrane bound HSPGs 
are the syndecans and glypicans. Major components of the 
ECM include perlecan, agrin, and collagen XVII. Heparan 
sulfate chains are variably sulfated at either carbon 3 or 6 of 
GlcNAc or oxygen 2 position of GlcA (Figure 1C, D).
Figure 2 is a schematic representation of the wide variety 
of chondroitin and heparan sulfate proteoglycans. As also 
depicted in Figure 2, PGs have different sizes, levels of glyco-
sylation, and cellular localization. These different character-
istics are plausible factors that determine the type of inter-
action PGs have with elongating neurites, which is a major 
agenda of this review.
Proteoglycans role in the inability for the CNS 
to repair following injury
The inability for the spinal cord to regenerate is a major 
reason for the long-term disabilities and high societal costs 
spinal cord injuries bare. As most tissues have an innate abil-
ity to regenerate, the innate CNS regeneration response does 
not enable full anatomical and functional recovery. As regen-
eration of neurons often occurs locally, in a process called 
“sprouting”, the new neuronal connections made are often 
insufficient in providing functional recovery, but can some-
times be further burdensome in the form of pathological 
pain (Harris, 1999; Shortland et al., 1997; Zhang et al., 2004; 
Zimmermann, 2001). This makes CNS injury a particularly 
challenging injury to overcome. Greater understanding of 
the physiological response following SCI reveals PGs to be 
culpable in preventing the injured spinal cord from regener-
ating. As with many damaged tissues, following injury to the 
spinal cord, a scar forms. This scar, commonly referred to as 
the glial scar, is caused by a proliferation of reactive astro-
cytes and acts as a barrier that surrounds the damaged tissue. 
The glial scar reduces the damaging secondary insults that 
can follow injury to the CNS, such as cytotoxic, excitotoxic, 
and oxidative insults (Beller et al., 2011; Rolls et al., 2009; 
Sofroniew, 2005). However, the formation of this scar is also 
responsible for inhibiting the regeneration of the injured 
spinal cord (Bovolenta et al., 1992; Hu et al., 2010; Rudge 
and Silver, 1990). Intriguingly, the formation of the glial scar 
is closely associated with increased expression of CSPGs.
A variety of CSPGs are elevated both acutely and chron-
ically following SCI and localized within the glial scar and 
surrounding areas. Following SCI in the rat, neurocan, brev-
ican, and versican expression was increased in the area sur-
rounding the injury up to 2 months post-injury. In addition, 
neurocan, tenascin-C, and NG2 were significantly increased 
and reached peak levels 8 days post-injury, while expression 
of other CSPGs, phosphacan and brevican, are increased and 
reach peak levels 1 month post-injury in the rat. These in-
creases in PG protein were localized to regions that contain 
fibronectin scar tissue (Jones et al., 2003; Tang et al., 2003). 
Furthermore, the expression of some CSPGs following spi-
nal cord injury is closely associated with the areas adjacent 
to the forward process of transected axons, appearing as a 
stop sign to a regenerating neuron (Jones et al., 2002).
The increase of PG expression within the glial scar and the 
inability for the injured spinal cord to grow beyond the glial 
scar implicates a direct role of CSPGs in the inability for the 
injured spinal cord to regenerate. In vitro experimentation 
has demonstrated CSPGs ability to inhibit neurite outgrowth 
and regeneration. For instance, PGs extracted from the epi-
center of a rodent SCI inhibited neurite outgrowth from 
various neuronal cell-types (McKeon et al., 1995). While, 
versican and brevican (which are elevated following injury) 
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Figure 1 Structural components of chondroitin sulfate and heparan sulfate glycosaminoglycans.
Structural components of chondroitin sulfate and heparan sulfate glycosaminoglycans. (A) Chondroitin sulfate chains are comprised of repeat-
ing disaccharide units of N-acetylgalactosamine (GalNAc) and glucuronic acid. GalNAc is either not sulfated, or sulfated at the 4, 6 or both 4 and 
6 carbon positions. (B) These chains are arranged by the formation of a 1,4-β-glycosidic linkage. (C) Heparan sulfated chains are comprised of 
repeating disaccharide units of N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcA). GlcNAc is either not sulfated, or sulfated at the 3 or 6 
carbon position. GlcA may be sulfated at the 2 carbon position. (D) Like chondroitin sulfate these disaccharides are linked through a 1,4-β-glyco-
sidic linkage. The chemical structures in Figure 1 were produced using Marvin Sketch Version 6.1.0, which was used under the ChemAxon Ltd. free 
educational license.
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Figure 2 Proteoglycans are proteins that vary in size, localization, and degree of post-translational modifications.
There are many different proteoglycans that vary in size and degree of glycosylation. In addition, the localization of these molecules varies depend-
ing on the type and tissue, as some are bound to the extracellular matrix through hyaluronan or collagen (top panel) or found in the membrane or 
excreted into the extracellular space (bottom panel).
(1,000 kDa)
(300 kDa)
DecorinBrevicanNeurocanVersicanAggrecan
(2,500 kDa)
350 kDa
250 kDa
150 kDa
100 kDa
350 kDa
50 kDa
90 kDa
Neuroglycan-C
Phosphacan
PTPζ
347
Beller JA, et al. / Neural Regeneration Research. 2014;9(4):343-355.
were demonstrated to contribute to the growth inhibitory 
activity of myelin, as treatment with β-xyloside (a PG syn-
thesis inhibitor) greatly increased the growth permissiveness 
of oligodendrocytes (producers of myelin) (Niederost et al., 
1999). In addition, CSPGs produced in reactive astrocytes, 
like those that makeup the glial scar inhibit neurite out-
growth in vitro (Bovolenta et al., 1997; Canning et al., 1996). 
The historical precedent for CSPGs ability to inhibit neurite 
outgrowth is discussed, in detail, later in the review. 
Further evidence for the role of CSPGs following SCI 
comes from animal models of SCI. Treatments that have 
directly targeted the CSPGs of the glial scar have been mod-
estly effective at promoting growth across the injury site and 
functional recovery in rodents. For instance, treatment of the 
injured spinal cord with the bacterial enzyme chondroitinase 
ABC (cABC), which removes the chondroitin sulfate chains 
of CSPGs, can improve neuronal growth across the glial scar 
and improve functional outcome (Bradbury and Carter, 
2011; Bradbury et al., 2002; Garcia-Alias et al., 2009; Huang 
et al., 2006; Massey et al., 2006; Tom et al., 2009). In addi-
tion, degradation of a specific CSPG core protein, aggrecan, 
enhances functional recovery following SCI (Tauchi et al., 
2012; Snow, et al., unpublished data).
The connection between SCI, CSPGs, and failed regener-
ation is based on experimental observations. The increase 
in PG expression in the glial scar, the ability for these PGs 
to inhibit neurite outgrowth, and the inability for neurons 
to grow across the glial scar suggests that there is a direct 
interaction between PGs and an outgrowing/regenerating 
neurite. Though this evidence implicates PGs as having a 
profound effect on neurite outgrowth the exact mechanisms 
responsible for these interactions are unknown. Therefore, it 
is the goal of our review to explain where and how we got to 
the current understanding of this interaction and where this 
field of research is heading. As PGs’ role following SCI has 
been, and continues to be, a major impetus for examining 
the exact mechanisms by which PGs interact with outgrow-
ing neurites, specifically, with the sensorimotor leading end 
of the neurite, the neuronal growth cone (Beller et al., 2013; 
Cajal, 1892; Letourneau et al., 1994). A deeper understand-
ing of this interaction will yield new modes of therapy aimed 
at improving neuroregeneration following SCI.
Traditional and novel methods to analyze PG 
interactions with neuronal growth cones,  
axons, and cell bodies
There are three major in vitro methods for analyzing the 
interaction of PGs with outgrowing neurons, neurites and-
growth cones.
Soluble PG outgrowth models
The simplest and first method used to analyze the influ-
ence of PGs on neurite outgrowth was the introduction 
of PGs in solution, i.e., delivering PGs in the media to at-
tached, outgrowing neuronal cells. The advantage to this 
method, still used, is that multiple concentrations of PGs 
can be easily and quickly tested for their effect on neurite 
outgrowth (Snow et al., 1996). The disadvantage to this 
approach is the physiological relevance. For instance, in the 
extracellular matrix, PGs are commonly physically attached 
to hyaluronan and other ECM molecules and not simply 
floating in the extracellular milieu (Frantz et al., 2010). This 
may alter the observed effect of the PG on the outgrow-
ing neurite, and it may allow for interactions with the PG, 
that when coupled to the ECM, may not be possible. For 
instance, when laminin, a growth permissive substrate for 
neurons, and aggrecan, a growth inhibitory CSPG, are both 
substratum adsorbed in vitro, the order of application of 
these compounds effects the behavior of the neurons (Con-
dic et al., 1999). In particular, when aggrecan was adsorbed 
to the substrata in the presence of laminin in solution, 
the aggrecan was more inhibitory than when the aggrecan 
was bound either before or after adsorption of laminin to 
the substratum. This suggests that an interaction between 
laminin and aggrecan is essential for the inhibitory nature 
of aggrecan. In addition, electrochemical and steric interac-
tions between the PG molecules themselves may be altered 
when not physically coupled to the ECM. These were early 
“lessons learned” and have shaped the specifics of more 
refined methods now in use. For example, to account for 
these interactions, methods in which PGs are substratum 
bound and presented directly to outgrowing neurites were, 
and are, also still widely used.
The “stripe assay” (also “patterned assay” or “choice assay”)
The “stripe assay” is a widely used patterned outgrowth assay 
developed to analyze the response of elongating neurites to 
CSPGs in much the same way a developing or regenerating 
neurite might encounter cells expressing CSPGs in vivo, e.g., 
the glial scar (Snow et al., 1990). The “stripe assay” uses an 
alternating pattern of substratum-bound growth-permis-
sive molecules, often laminin but also fibronectin, collagen, 
NCAM, or others, and the experimental PG (Snow et al., 
1990; 2001). Commonly, neuronal explants or dissociated 
cells, e.g., sensory dorsal root ganglion (DRG), are placed 
alongside a substrate-bound PG stripe and the effect on 
neurite outgrowth is determined in a variety of ways (i.e., in-
hibition of forward elongation by examining the number of 
neurites turning versus crossing the stripe; growth cone mor-
phology; growth cone retraction, etc.). For instance, when 
the CS/KSPG, aggrecan, the V2 splice variant of versican, 
and tenascin, were tested using the “stripe assay”, there was a 
significant reduction in the number of neurites growing on 
the stripes containing the PG (Krull et al., 1994; Schmalfeldt 
et al., 2000; Snow et al., 1990; Treloar et al., 2009). In addi-
tion, this method is also extremely useful in examining other 
effects than just total outgrowth. For example, the “stripe as-
say” was also used to measure the effect PGs have on calcium 
signaling, rate of neurite elongation, and filipodia behavior 
(Snow et al., 1994; 1996). Further, the method was also used 
to develop semi-automated approaches to quantitatively 
determine the relative level of inhibition of various PGs by 
calculating an “inhibitory index” (Hynds and Snow, 2002). 
More recently, the method was adapted to measure subtle 
changes in growth cone morphology, filipodia behavior, and 
growth cone velocity in response to structural variants of 
the CSPG aggrecan (Beller et al., 2013). This highly useful 
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and commonly employed method provides a means to ex-
amine the effect a steep change from a growth permissive to 
a growth inhibitory substratum has on neuronal outgrowth. 
This represents the pattern of CSPG an outgrowing neurite 
may encounter when approaching the ECM presented by the 
glial scar. Next we describe another type of patterned assay 
that examines a gradient of PG expression, i.e., a less steep 
presentation of PGs. This model represents a different way 
the PGs expressed by glial scars or other key depositions of 
ECM may present themselves to outgrowing neurites.
Gradient assays 
Gradient assays facilitate the examination of the effect a 
more gradual change in concentration of substrate-bound 
PG and growth-permissive substrata have on neurite out-
growth. There are two major methods to examine PG 
gradients, namely the “step-gradient” (Snow and Letour-
neau, 1992) and the “spot gradient” (Tom et al., 2004). The 
“step-gradient” is a modified stripe assay with increasing 
concentrations of PGs on each subsequent step of the gradi-
ent. The “spot-gradient” is a gradient formed by adhering a 
spot of PG to the substratum (often laminin) and diffusion 
of the PG around the initial spot forms a gradient. These 
assays have been used to study the effects of an approach-
ing growth cone interacting with increasing concentrations 
of PG, the formation and behavior of dystrophic growth 
cones, identifying PG receptors, and to model the effect PGs 
have on neurite outgrowth following macrophage induced 
axonal dieback (Busch et al., 2010; Shen et al., 2009; Snow 
and Letourneau, 1992; Tom et al., 2004). Together these 
substratum-bound methods used to analyze the PG-neurite 
interaction successfully model various aspects of neuronal 
interactions with the glial scar formed following injury, and 
represent the predominate methods currently used to study 
this interaction.
Tracing the history of proteoglycan  
interactions with neuronal growth cones
The complex structure of PGs suggests a number of ways a 
neuronal growth cone may interact with PG molecules (Fig-
ure 3). Though the field has grown since its beginnings (Car-
bonetto et al., 1983; Snow et al., 1990; Verna et al., 1989), 
there is no consensus as to what part of the PG molecule is 
the key player. There are at least two possible ways in which 
a PG can physically interact with a neuronal growth cone in 
a receptor-mediated fashion:  interactions through the PG 
core protein or through the associated GAG chains. 
Interactions via the proteoglycan core proteins.
The hypothesis that the core protein is involved in neurite 
inhibition arose from two studies conducted in 1991, in 
which, CSPGs were extracted from rat brain and were en-
zymatically degraded to remove their attached GAG chains.
Intriguingly, these two studies revealed different effects of 
the extracted PG purifications. Specifically, CSPGs extracted 
from rat brain were adsorbed to the bottom of cell culture 
plates as either intact CSPGs, the isolated CSPG core pro-
teins (no GAG chains), or the isolated GAG chains. There 
was an increase in neurite outgrowth of neocortical neurons 
in response to the intact CSPGs and the intact CSPG core 
proteins, but not with the purified GAG chains (Iijima et 
al., 1991). This suggested that CSPG core proteins promote 
neurite outgrowth, while GAG chains have no effect. In 
contrast, CSPGs extracted from 10-day-old rat brain and 
directly added to the media of PC12D cell cultures caused 
an opposite effect. Intact CSPGs and CSPGs with the GAG 
chains enzymatically removed inhibited neurite outgrowth. 
In addition, the purified GAG from this extraction did not 
inhibit neurite outgrowth, further suggesting that the core 
proteins themselves were responsible for inhibition (Oohira 
et al., 1991). Although the measured effects on neurite out-
growth of these two early experiments were different, neurite 
outgrowth promotion in the first and inhibition in the latter, 
they both suggested that PGs effect on neurite outgrowth 
was dependent on the core protein. 
Further experimentation analyzed specific PG core pro-
teins and their effect on neurite outgrowth. In 1994, exper-
imentation with purified NG2 further supported the role 
of CSPG core proteins involvement in neurite inhibition. 
Embryonic rat DRG neurons outgrowth was inhibited by 
intact NG2 and was also inhibited after enzymatic removal 
of CS chains by chondroitinase ABC, thus suggesting a direct 
role of the NG2 core protein in neurite outgrowth inhibition 
(Dou and Levine, 1994).
A repulsive and differentiation-promoting influence of the 
phosphacan core protein was demonstrated by Maeda and 
Noda (Maeda and Noda, 1996). In brief, cortical neurons ex-
posed to purified phosphacan (intact and following chABC/
keratanase digestion) displayed less neurite outgrowth and 
enhanced morphological differentiation. Similarly, brevican 
bound to astrocyte cell surfaces through the C-terminal por-
tion of the core protein, inhibited neurite outgrowth in vitro 
in cerebellar granule cells independent of GAG chains (Ya-
mada et al., 1997). In 1999, evidence suggesting that differ-
ent neuronal types may respond differently to the same PG 
was reported. The mouse homolog of phosphacan (DSD-1), 
caused opposing effects on neurite outgrowth dependent on 
the neuronal cell type, as the core protein inhibited neurite 
outgrowth from DRG explants and did not affect outgrowth 
of hippocampal neurons (Garwood et al., 1999). This im-
portant study not only strengthened the belief that core 
proteins affect outgrowth, but also suggested the important 
idea that different cell-types react differently to PGs. Further 
studies of phosphacan and neurocan revealed that core pro-
teins inhibited neurite outgrowth of retinal ganglion cells in-
dependent of chondroitinase digestion (Inatani et al., 2001). 
In 2003, the outgrowth of peripheral and CNS-derived neu-
rons in response to versican V2 was measured. Purified ver-
sican V2 core protein was inhibitory to neurite outgrowth, as 
an undigested PG, following digestion with chondroitinase 
ABC and removal of N- and O-linked oligosaccharides. This 
versican V2 inhibited neurite outgrowth from both peripher-
al and CNS-derived neurons. Only digestion of the core pro-
tein itself abolished versican V2 mediated neurite outgrowth 
inhibition (Schmalfeldt et al., 2000). More recently, PI3-K 
activation was measured in response to neuroglycan-C and 
a recombinant neuroglycan-C that lacked associated GAG 
chains. Both the intact and recombinant neuroglycan-C ac-
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Figure 3 Timeline of advancements in the understanding of the role proteoglycans play in neuronal outgrowth (Selective list; not intended to 
be exhaustive).
1980
Glycosaminoglycans inhibit neurite
outgrowth on fibronectin.
(Carbonetto et al., 1983)
Different glycosaminoglycans affect 
neurite outgrowth differently.
(Verna et al., 1989)
Depending on the neuronal cell-type 
GAGs and core proteins have 
differential effects.
(Garwood et al., 1999)
PTPsigma respresents a receptor for 
chondroitin sulfate and heparan sulfate.
(Shen et al., 2009; Coles et al., 2011)
Variations in core protein fragmentation, GAG 
chain length and
amount differentially effect growth cone response.
(Beller et al., 2013)
High-throughput neurite outgrowth assay to determine 
contributions of PG structure on neurite outgrowth.
(Beller et al., 2014)
Keratan sulfate and chondroitin 
sulfate are necessary for inhibitory
action of aggrecan.
(Snow et al., 1990)
Chondroitin sulfate is the 
major inhibitory GAG.
(Snow et al., 1992; Friedlander et 
al., 1994; Milev et al., 1994)
Core proteins are responsible for 
proteoglycans effect on neurite 
outgrowth.
(lijima et al., 1991; Oohira et al., 1991)
Different core proteins have different 
direct effects on neurite outgrowth.
(Dou et al., 1994; Madea et al., 1996; 
Yamada et al., 1997)
Spliceforms of core proteins differentially 
effect neurite outgrowth.
(Schmalfeldt et al., 2000; Wu et al., 2004) Different sulfation patterns of chondroitin 
sulfate are more or less inhibitory to 
neurite outgrowth.
(Gilbert et al., 2005; Wang et al., 2008; 
Karumbaiah et al., 2011)
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tivated the PI3-K pathway and promoted neurite outgrowth, 
suggesting the core protein was involved in both (Nakanishi 
et al., 2006). Based on this long list of results from a variety 
of laboratories, it is clear that PG core proteins regulate neu-
rite outgrowth, although the specific mechanisms and differ-
ences between results are not well understood. 
Interactions via the glycosaminoglycan chains
The alternative, and to many, the leading hypothesis in the 
field of PGs influence on neurite outgrowth is that there 
are direct interactions between the elongating/regenerating 
growth cone and the GAG chains of PGs. This hypothesis is 
supported by many results that conflict with those discussed 
above. For example, in 1982, the first evidence suggesting 
the role of GAG chains in the control of neurite outgrowth 
was reported, while experimenting with heparan sulfate. 
Rat sympathetic neurons were placed onto matrix produced 
by cultured bovine endothelial cells. The neurons extended 
neurites in the absence of nerve growth factor. Only treat-
ment with heparanase abolished this neurite extension in the 
absence of NGF. This pivotal study led to the hypothesis that 
PG GAG chains have a direct effect on neurite outgrowth 
(Lander et al., 1982). In 1990, a pivotal study examining 
the proteoglycan aggrecan (at the time known as KS/CS-
PG) was published. In this report, a novel, and now classic, 
method for testing neurite outgrowth was presented (see 
Ways to Measure Outgrowth). Using enzymatic digestion, it 
was determined that KS and CS were essential for complete 
inhibition (Snow et al., 1990). Following this study, in 1991, 
a keratan sulfate proteoglycan extracted from developing 
chick CNS inhibited neurite outgrowth in vitro and the in-
hibition of this PG was abolished with keratanase treatment 
(Cole and McCabe, 1991). These three studies presented an 
alternative hypothesis to that presented above, in particular, 
that the GAG chains of PGs were responsible for imparting 
either the growth promoting or inhibiting activity of PGs.
In 1994, the effect of neurocan and phosphacan on the 
adhesion molecules N-CAM and Ng-CAM were described. 
N-CAM and Ng-CAM are members of the cadherin family 
and are integral mediators of neurite outgrowth, as cadher-
ins act as substrates for neuronal adhesion. Neurocan and 
phosphacan bind to N-CAM and Ng-CAM and inhibit neu-
rite outgrowth and cell attachment. In addition, the binding 
of neurocan and phosphacan to N-CAM and Ng-CAM was 
significantly reduced following chondroitinase digestion, im-
plicating the role of neurocan and phosphacan GAG chains 
in the inhibition of neurite outgrowth and cell adhesion 
(Friedlander et al., 1994; Milev et al., 1994). Further sup-
porting the role of GAG chains in outgrowth determination, 
in 1995, chemical inhibition of GAG formation by treating 
astrocytes with beta-D-xylosides or sodium chlorate caused 
a significant increase in neurite outgrowth in treated-astro-
cyte-conditioned media and on the treated-astrocytes them-
selves (Smith-Thomas et al., 1995). Additionally, in 1999, 
NG2 produced by astrocytes with CS chains attached was 
inhibitory to DRG neurons, while removal of NG2 CS chains 
was growth permissive (Fidler et al., 1999). This suggests 
that GAG formation is necessary for the inhibitory activity 
of astrocytic PGs, like those found in the injured spinal cord.
Thus, both components of PGs have measureable effects 
on neurite outgrowth. However, the mechanisms of each of 
these regulatory effects are not well delineated and underlie 
the basis of many lines of current research in the field (Beller 
et al., 2013; Brown et al., 2012; Dickendesher et al., 2012; 
Matsuo and Kimura-Yoshida, 2013; Yu et al., 2013).
New ways of thinking about the interaction  
between PGs and neurite outgrowth
HSPGs versus CSPGs: Go versus Stop
As reviewed above, there is a large amount of uncertainty 
as to how PGs can elicit such a diverse spectrum of effects 
on neurite outgrowth. There is no model that can predict 
the effect a particular PG will have on an outgrowing neur-
ite solely based on the type of core protein. However, when 
comparing different GAG types a clearer delineation can 
be drawn. In particular, the differences in the response to 
HSPGs versus CSPGs.
As presented earlier, Lander et al.’s study conducted in 
1982, showed that removal of heparan sulfate (HS) through 
the action of heparanase abolishes the NGF-independent 
outgrowth of sympathetic neurons, thus promoting neurite 
outgrowth (Lander et al., 1982). In agreement, outgrowth of 
spinal cord neurons, chick retinal neurons, motor neurons 
and PC12 cells were also promoted by HSPGs (Campagna et 
al., 1995; Hantaz-Ambroise et al., 1987; Kim et al., 2003). It is 
widely suggested that the growth promoting effect of HSPGs 
is due to their ability to bind and interact with growth fac-
tors. For instance, the transmembrane HSPG syndecan-3 is a 
receptor for the glial cell-derived neurotrophic factor (GDNF) 
and syndecan-3 binding to GDNF mediates cell spreading 
and neurite outgrowth. In addition, knockout of syndecan-3 
in mice caused a reduction in cortical GABAergic neu-
rons, suggesting an important role in cortical development 
(Bespalov et al., 2011). Similarly, the cell-surface-attached 
HSPGs (i.e., glypican, perlecan, and agrin) are important 
modulators of fibroblast growth factor signaling (Matsuo 
and Kimura-Yoshida, 2013). HSPGs also interact with oth-
er neurite outgrowth regulating proteins. For instance, the 
growth repulsive cue semaphorin-1a (for more discussion of 
semaphorins; see Shen et al. in this issue) was ineffective in 
motor neurons lacking the HSPG perlecan (Cho et al., 2012). 
HSPGs also interact with Netrin-DCC (growth permissive), 
and Robo-Slit (growth inhibitory) signaling to coordinate 
the lateral positioning of dopaminergic axons leading into 
the spinal cord by modulating the repulsive cues produced by 
the Robo-Slit interaction (Kastenhuber et al., 2009). Indeed, 
HSPGs appear to transduce a positive cue to outgrowing 
neurites by promoting continued growth.
Unlike the HSPGs, CSPGs provide inhibitory cues to out-
growing neurites. For instance, brevican, aggrecan, NG2, 
neurocan and phosphacan are inhibitory to DRG neurons, 
cortical neurons, cerebellar granule neurons, and retinal 
ganglion cells, respectively (Beller et al., 2013; Dou and 
Levine, 1997; Inatani et al., 2001; Snow et al., 1990; Yamada 
et al., 1997). However, there is conflicting data, which sug-
gests that not all CSPGs interact with neurons to produce 
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the same effect, and that this may be CSPG dependent or 
neuronal cell-type dependent. For instance, DSD-1, the 
mouse homolog of phosphacan, inhibited neurite outgrowth 
from neonatal DRG neurons yet, it had no effect on embry-
onic hippocampal neurons (Garwood et al., 1999). Further, 
different forms of the same CSPG may elicit different effects 
in a class of neuron. For instance, the short isoform of phos-
phacan, a non-proteoglycan variant known as receptor pro-
tein tyrosine phosphatase-β (RPTPβ), promoted outgrowth 
of neonatal cortical neurons (Garwood et al., 2003). In 
addition, differences in splicing of a particular PG can affect 
its effect on neurite outgrowth. For instance, the V1 isoform 
of versican promoted neurite outgrowth of hippocampal 
neurons, whilst the V2 isoform inhibited neurite outgrowth 
of hippocampal neurons, retinal ganglion and DRG neurons 
(Schmalfeldt et al., 2000; Wu et al., 2004). Other than neuro-
nal cell-type, the form of the PG, or the splice variants, the 
differential effect of particular CSPGs on neurite outgrowth 
may be explained by the differences in the varied forms of 
sulfation of the GAGs. This idea is one of the more recent 
developments in the study of PGs, specifically, the effect of 
different sulfation patterns on neurite outgrowth.
CSPG sulfation may affect signal
Investigating the effects that sulfation patterns and epitopes 
have on neurite outgrowth is taking the forefront as the 
most intricate understanding of the interaction of proteo-
glycans and neurite outgrowth (Habuchi et al., 2004; Holt 
and Dickson, 2005). As explained earlier, there are four 
major forms of CS, CS-2, CS-4, CS-6, and CS-4,6. Initial 
experimentation examining the activity of these different 
sulfation forms of GAGs studied purified preparations of 
the CS chains alone. Though unlikely to perfectly mimic 
the effect of CS attached to the core protein, these exper-
iments did begin to unravel the role sulfation may play 
in the differential response to CSPGs. These experiments 
have demonstrated that depending on the neuronal cell-
type and predominant sulfation form of the PG, differen-
tial responses in neurite outgrowth were reported. When 
CS-4 and CS-6 were added into the cell media, adhesion 
of thalamic and hippocampal neurons to laminin and po-
ly-l-lysine were reduced. However, only thalamic neuron 
outgrowth was affected as CS-6 increased the amount of 
outgrowth from thalamic neurons (Fernaud-Espinosa et 
al., 1994). Similarly, in a different study, CS-4 was found 
to be strongly inhibitory to cerebellar granule cells, while 
CS-6 was not (Wang et al., 2008). These results seem to 
suggest that one can predict a particular neuronal cell-type 
response based on the interaction with CS specific sulfation 
pattern. However, the association is not necessarily clear. 
For instance, substrate bound CS-4,6 increased neurite 
outgrowth of embryonic hippocampal neurons, while it 
strongly inhibited DRG neurite outgrowth (Gilbert et al., 
2005). In partial agreement with the previous study, genetic 
suppression of CS-4,6 in astrocytes through siRNA target-
ing of the sulfotransferases that produce the 4,6 sulfation 
pattern, produced astrocytic proteoglycans with reduced 
inhibition of neurite outgrowth in embryonic cortical neu-
rons (Karumbaiah et al., 2011). Though developments are 
expanding the role different sulfation patterns play in the 
regulation of neurite outgrowth, the mechanism(s) and the 
target(s) involved in this interaction are not known.
How do CSPGs regulate neurite outgrowth? 
The regulation of neurite outgrowth is often envisioned as the 
summation of negative and positive signals received by a neu-
ron through receptor-mediated mechanisms. Though CSPGs 
may act as a physical wall or barrier to extending neurites, it is 
likely that CSPGs interact with an outgrowing neurite either 
directly or indirectly with receptors located on the neuron.
Do PGs interact with the neuronal growth cone, axon, or 
cell body?
Anatomically, the ECM surrounds all parts of cells includ-
ing the growth cone, axon and cell body. Less clear is what 
part or parts of a neuron are interacting with the PGs in 
the ECM. Immunocytochemical and immuno-electron mi-
croscopic analysis of the distribution of phosphacan in the 
olfactory nerve displayed a widespread distribution of the 
PG on both the surfaces of neuronal cell bodies and neurites 
(Nishizuka et al., 1996). In the CNS, neuronal cell bodies are 
commonly surrounded by structures known as perineuronal 
nets (PNN), which are enriched in proteoglycans (Celio and 
Blumcke, 1994). In addition, these PNNs regulate synaptic 
plasticity and synapse formation, by both interacting with 
the cell body and neurites growing towards the surrounded 
cell body (Pizzorusso et al., 2002; Wang and Fawcett, 2012). 
Work conducted by our group previously demonstrated that 
contact with CSPGs through either the cell body or growth 
cone caused a significant increase in intracellular [Ca2+] 
(Snow et al., 1994). Neuronal cell bodies in contact with 
CSPGs located in Schwann cell membranes extend neurites 
that are inhibited by contact with CSPG, however when the 
Schwann cell membrane CSPGs are digested with chondroiti-
nase, neuronal cell bodies in contact with these Schwann 
cells extend neurites that are no longer inhibited by contact 
with CSPGs (Castro and Kuffler, 2006). Likewise, postnatal 
cerebellar granule cell bodies and neurites are both repulsed 
through contact with CSPGs (Kaneko et al., 2007). It is not 
clear at what locale the CSPGs are eliciting their effect.
Work in our group has focused on the rapid changes oc-
curring following growth cone contact with CSPGs. Follow-
ing growth cone contact with CSPG, there are rapid changes 
in filipodia number, length, growth cone width, growth cone 
length, and growth cone velocity (Beller et al., 2013). In ad-
dition, the majority of studies are focused on the interaction 
of the neuronal growth cone’s contact with CSPGs, though 
CSPG contact with the neuronal cell body also affects the 
interaction of the neuronal growth cone with CSPG. For in-
stance, neurons have the ability to“adapt” to the presence of 
CSPGs contacting the cell bodies through the upregulation 
of integrins and are no longer inhibited by CSPGs (Condic et 
al., 1999; Lemons et al., 2005). It is clear that both the neuro-
nal cell body and growth cone interact with CSPGs. However, 
the similarities and differences in the neuronal response and 
their dependence on where the CSPG is contacted is unclear. 
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PGs as receptor “shuttles”
PGs may interact with an outgrowing neurite by acting as 
a ligand “shuttle” and present a bound ligand to a recipient 
receptor. For instance, the syndecans are a class of HSPG, 
which play a key role in growth factor signaling sensitivity. 
Through the interaction with the 2-O-sulfated iduronic 
acid units of the HS on syndecan, many growth factors are 
able to bind. Once bound to the HS, the growth factor is 
presented and bound to its respective receptor. Signaling 
pathways dependent upon syndecan binding include the 
GDNF, FGF, Wnt, VEGF, and HGF pathways (Chen et al., 
2013; Chernousov and Carey, 1993; Tkachenko et al., 2005). 
In particular, removal of N-syndecan HS chains reduced 
neurite outgrowth in vitro and ex vivo in response to growth 
factor stimulation, thus suggesting a growth-permissive 
role of N-syndecan binding (Kinnunen et al., 1996). N-syn-
decan is implicated to signal through a Src kinase signaling 
pathway, contribute to the development of axon tracts, and 
the process of hippocampal long-term potentiation, all re-
quiring neurite outgrowth (Kinnunen et al., 1998; Lauri et 
al., 1999). Syndecans represent a way a PG may affect neu-
rite outgrowth as a receptor or “shuttle” for growth factors. 
However, there is also evidence of PGs as a ligand, binding to 
cell-surface receptors.
PGs as ligands 
Protein tyrosine phosphatase sigma (PTPσ) was recent-
ly discovered to be a receptor for CSPGs. This represents 
an important step in understanding the manner in which, 
CSPGs inhibit neurite outgrowth. Through a series of elab-
orate experimentation, PTPσ bound specifically to the CS 
chains of CSPGs, and inhibited neurite outgrowth (Shen et 
al., 2009). Further, HSPGs also bound to the PTPσ receptor 
and acted as a switch between growth-promotion and inhibi-
tion. As binding to CSPG reduced neurite outgrowth, while 
binding to HSPG increased neurite outgrowth (Coles et al., 
2011). PTPσ is not the only CSPG receptor as two members 
of the Nogo receptor family are also CSPG receptors. NgR1 
and NgR3 knockout mice have reduced CS binding and an 
enhanced ability for axonal regeneration following optic 
nerve crush, and reduced outgrowth inhibition in neurons 
cultured on CSPG (Dickendesher et al., 2012). Initial steps 
at elucidating the pathways these receptors signal through is 
underway. Global analysis of the neuronal phosphoproteome 
in response to CSPGs identified a number of proteins whose 
phosphorylation state is regulated by CSPGs. The majority of 
these proteins are found in important cellular pathways that 
regulate cell morphology, nervous system development, and 
RNA post-transcriptional modifications (Yu et al., 2013).
Knowledge of PGs role in the CNS has evolved overtime 
from the discovery that PGs produced by cultured endothe-
lial cells improve neurite outgrowth (Lander et al., 1982), to 
the conclusion that both the PG core protein and GAG chain 
affect neurite outgrowth in a neuron cell-type specific man-
ner (Beller et al., 2013; Nakanishi et al., 2006; Snow et al., 
1990). The added knowledge on how PGs interact with out-
growing neurites allows for the continuing acceleration of 
knowledge, as the role of PGs as receptor and ligand opens 
up a new field of mechanistic and pharmacological research 
(Beller et al., in press; Dickendesher et al., 2012; Shen et al., 
2009; Tkachenko et al., 2005).
Future directions 
Though the 30+ years of research into the role of PGs in the 
regulation of neurite outgrowth has not led to a consensus 
on the way they interact with an outgrowing neurite, many 
tools and ideas integral to cracking the PG code have been 
revealed. For instance, the recent discovery that PTPσ, NgR1 
and NgR3 are CSPG receptors opens the path to a new field 
of pharmacology. Now that CSPG targets are identified, 
pharmacological analysis of the varying post-translational 
modifications can be conducted. The binding affinities of 
these substrates to the receptors can be compared to their 
effect on neurite outgrowth and the relationship between 
structure and function can be understood. In addition, 
development of a high throughput method to analyze a large 
number of proteoglycans on different neuronal cell types 
will enhance our ability to determine neuronal specificity 
and their response to PGs. For instance, through a series of 
elaborate experimentation, a synthetic GAG containing only 
CS-4,6 was found to bind with high affinity to the PTPσ 
receptor and inhibited neurite outgrowth of dissociated and 
intact DRG neurons. In addition, masking of this epitope 
through a specific monoclonal antibody against CS-4,6 pro-
moted neuroregeneration through the CSPG-rich glial scar 
(Brown et al., 2012).
Our laboratory is currently producing CSPGs that have 
defined sulfation patterns. Through reverse transcriptase 
PCR we determined that HEK293T cells expressed all the 
carbohydrate sulfotransferases that produce each of the 
CSPG sulfation patterns, specifically CS-2, CS-4, CS-6, and 
CS-4,6. By producing stable transfectants of these HEK293T 
cells with shRNA directed towards specific CHSTs, we are 
producing CSPGs that lack one of the specific sulfation pat-
terns. This allows us to determine the contribution of each 
of these sulfation patterns on neurite outgrowth. This will 
require a large number of outgrowth assays. Therefore, our 
laboratory has developed a high-throughput assay (Beller 
et al., in press). This assay will allow the analysis of a large 
number of proteoglycans and neuronal cell-types, in order 
to determine the contribution of each sulfation pattern, pro-
teoglycan core protein, and post-translational modification. 
Results from these studies may lead to the development of 
novel pharmacological approaches to enhance regeneration 
of the injured spinal cord. 
Conclusion
The complexity of both PG structure and the process of neu-
ronal outgrowth makes deciphering the interaction between 
PG and neurite an arduous task. Due to the high variability 
in PG composition, the limitations in the models available 
for assessing PG effect, the multiple ways PGs and neurites 
are capable of interacting; a full understanding of the mech-
anism(s) at play are likely far off. However, it is clear that 
PGs play an important role in the process of neurite out-
growth and contribute to the inability of the injured spinal 
cord to regenerate. With continued persistence, a clearer pic-
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ture of the PG neurite interaction may lead to the ability to 
not only regenerate, but also rewire, the injured spinal cord 
and brain.
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